{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.21","upperLimit":"0.41","value":"0.308"},{"groupId":"OG001","lowerLimit":"0.31","upperLimit":"0.43","value":"0.370"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 2 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.20","upperLimit":"0.55","value":"0.337"},{"groupId":"OG001","lowerLimit":"0.15","upperLimit":"0.21","value":"0.178"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 6 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.25","upperLimit":"0.53","value":"0.387"},{"groupId":"OG001","lowerLimit":"0.16","upperLimit":"0.36","value":"0.262"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 24 hours post-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Ratio to baseline was calculated dividing post-baseline measurements by the baseline measurement. Single dose Pd data on Day 1 were summarized by dose level, such that all 10 mg arms were combined as descriptive statistics of PK were only calculated for N greater than (\\>) 2 in which a measurement of greater than (\\>) lower limit of quantification (LLOQ) represents a valid measurement.","dispersionType":"Full Range","groups":[{"description":"Participants received M3258 at a dose of 10 mg orally, QD or twice per week until disease progression.","id":"OG000","title":"M3258 10 mg QD or Twice Per Week"},{"description":"Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG001","title":"M3258 20 mg Twice Per Week"}],"paramType":"MEAN","populationDescription":"The Pharmacodynamic (Pd) population included all participants who received at least one dose of study intervention, had no clinically important protocol deviations or important events affecting Pd, and provide at least one measurable Pd endpoint post-dose. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure and \"Number Analyzed\" signifies those participants who were evaluable for specified timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline (Pre-dose), 2, 6 and 24 hours post-dose on Cycle 1 Day 1 (each Cycle is of 28 days)","title":"Part A: Single Dose: Ratio to Baseline in Large Multifunctional Protease 7 (LMP7) Activity at Cycle 1 Day 1","type":"SECONDARY","unitOfMeasure":"ratio"}